

## ASX RELEASE

### Volpara Quarterly Results and Investor Webinar Notification

Wellington, NZ, 19 October 2021: [Volpara Health Technologies](#) (“Volpara,” “the Group,” or “the Company”; ASX: VHT), a global health technology software leader providing an integrated breast care platform for the delivery of personalised breast care, will be hosting an investor webinar on **Tuesday 26<sup>th</sup> October 2021** at 11:00am NZDT (Auckland/Wellington), 9:00am AEDT (Sydney/Melbourne) to update shareholders following the release of its Appendix 4C and quarterly financial results.

The call will be hosted by Group CEO Dr Ralph Highnam, CFO Craig Hadfield and EVP US Sales & Marketing Jill Spear.

#### **Webinar details**

**Date:** Tuesday 26<sup>th</sup> October 2021

**Time:** 11:00am NZDT (Auckland/Wellington), 9:00am AEDT (Sydney/Melbourne),

**To register:** [https://us02web.zoom.us/webinar/register/WN\\_cCupbrUgRDuiS5UV0vMFcA](https://us02web.zoom.us/webinar/register/WN_cCupbrUgRDuiS5UV0vMFcA)

**Dial in details:** Will be provided to you upon registration

Participants will be able to submit questions during the webinar via a written Q&A facility displayed at the bottom of the webinar screen or can submit them in advance to [hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com).

## **ENDS**

#### **Authorisation & Additional Information**

This announcement was authorised by the Group CEO, Dr Ralph Highnam.

For further information, please contact:

**Corporate enquiries**  
Ralph Highnam, CEO  
Volpara Health Technologies Ltd  
[ralph.highnam@volparahealth.com](mailto:ralph.highnam@volparahealth.com)  
t: +64 21 149 0541

**Investor enquiries**  
Hannah Howlett  
WE Communications  
[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)  
t: +61 450 648 064

**Media enquiries**

Evonne Grosso

WE Communications

[WE-AUVolpara@we-worldwide.com](mailto:WE-AUVolpara@we-worldwide.com)

t: +61 450 603 182

**About Volpara Health Technologies Limited (ASX: VHT)**

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020 and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health, LLC (risk and genetics software). VHT is based in Wellington, New Zealand.

For more information, visit [www.volparahealth.com](http://www.volparahealth.com)